Kinesiotaping in Trauma (KIT)

July 27, 2023 updated by: Onze Lieve Vrouwe Gasthuis
Rationale: Patients with acute traumatic injury to the shoulder or chest wall in de Emergency Department (ED) usually have intense pain. The patient normally is treated with oral analgesics as standard care and in shoulder injury with a sling. Pain of the shoulder or chest wall increases with movement of the affected arm and chest. Kinesiotaping is offered regularly as an additional pain treatment, but there is no hard evidence about its effectiveness. A randomized pilot study in OLVG (Bakker 2022) showed the pain decreasing more when using kinesiotaping comparing to no tape. However, a placebo-effect could not be ruled out and the pilot data need confirmation in a large cohort of patients to study the effectiveness of additional treatment with kinesiotaping in terms of pain, comfort and patient satisfaction.

Study Overview

Detailed Description

Objective: The primary aim of this study is to evaluate the effect of kinesiotaping on number of patients with clinically meaningful pain reduction after 1 week in patients with acute traumatic injury in shoulder or chest wall, compared to sham tape and no tape. The secondary aims are to assess the effect of kinesiotaping on pain reduction at 15 min, 3 weeks and 8 weeks, and the effects on the skin, use of oral analgesics, independence, activity pattern, progress of pain symptoms, comfort and patient satisfaction at 1, 3 and 8 weeks. Also the need of physiotherapy is one of the secondary aims.

Study design: Parallel randomized controlled trial with three arms

Study population: Patients of or over 18 years old with an acute single shoulder or chest wall injury (rib fracture, disruption of the acromioclavicular (AC) joint Tossy type 1 and 2, not or hardly dislocated fracture of clavicle or proximal humeral bone).

Intervention (if applicable): One group will receive treatment with kinesiotaping, another group receives sham taping (no elastic tape) and the third group receives no taping. This treatment is additional to the general treatment with oral analgesics and a sling (when shoulder injury).

Main study parameters/endpoints: The main study parameter is the proportion of patients who experienced a clinically meaningful reduction in pain score (≥2 points on NRS) at week 1 compared to T1. The kinesiotape group will be compared to the sham group and to the control group.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

At 15 minutes after receiving kinesio tape, sham tape or no tape, 1 week, 3 weeks and 8 weeks after visiting the emergency department the pain of these patients is evaluated using NRS by the Brief Pain Inventory (BPI). The effect of use of oral analgesics (questionnaire), on the skin (questionnaire), on independence, activity pattern and progress of pain symptoms (Groningen Activity Restriction Scale (GARS)), comfort and patient satisfaction (Global Perceived Effect (GPE-DV)) is evaluated after 1, 3 and 8 weeks. Physiotherapy is elevated after 8 weeks. Due to the limited seriousness of the injury and the non-invasive nature of the interventions, any serious complication or adverse event is not expected. Benefits of participating this study could be pain reduction in the affected body part.

Study Type

Interventional

Enrollment (Estimated)

387

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Maro Sandel, MD, PhD
  • Phone Number: +310205999111
  • Email: m.sandel@olvg.nl

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • ≥18 years
  • Acute injury (occurred <24 hours ago)
  • Single shoulder or chest wall injury, which includes one of the following injuries:

    • rib fracture
    • disruption of the AC-joint Tossy type 1 and 2
    • not or hardly dislocated fracture of the clavicle
    • Not or hardly dislocated fracture of the r proximal humeral fracture

Exclusion Criteria:

  • • Patients younger than 18 years

    • Incapacitated persons
    • Refusal of participation
    • Intubation indication
    • Decrease of Consciousness
    • Hemodynamic instability
    • 3 or more rib fractures
    • Rib fracture rib 1-3
    • Indication for surgery
    • Hospitalization required
    • Presence of a haemo- or pneumothorax with chest drain indication
    • Already known with allergy for adhesive tape
    • Patients with very thin or loose skin on the applicable body part
    • Skin infection/irritation or open wound on the applicable body part
    • Patients who do not speak Dutch or English

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Kinesiotape
Patients receives the additional treatment with kinesiotaping (and also standard treament)
leuko tape classic is used in this study to explore the possible placebo effect of kinesiotape
Other Names:
  • non elastic tape
standard treatment is the treatment with oral analgesics and a sling (if shoulder injury)
Sham Comparator: sham tape
patient receives an additional treatment with sham tape (without elastic features) (and also standard treatment)
standard treatment is the treatment with oral analgesics and a sling (if shoulder injury)
Kinesio tape is a thin, elastic tape that applies pressure to the skin (because of the elasticity of the tape), reducing pain by reducing nociceptive stimulation.
Other Names:
  • Leukotape K
  • medical taping
No Intervention: control group
patient receives the standard treamtment without additional tape treatment

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
number of patients with clinically meaningful pain reduction
Time Frame: 1 week
To evaluate the effect of kinesiotaping on number of patients with clinically meaningful pain reduction (Brief Pain Inventory (BPI)) after 1 week in patients with acute traumatic injury in shoulder or chest wall, compared to sham tape and no tape (2 comparisons).
1 week

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
number of patients with clinically meaningful pain reduction
Time Frame: after 15 minutes, 3 weeks and 8 weeks
the proportion of patients who experience a clinically meaningful reduction in pain score (≥2 points on NRS by BPI). The kinesiotape group will be compared to the sham group and to the control group (2 comparisons).
after 15 minutes, 3 weeks and 8 weeks
evaluating skin defects by questionnaire
Time Frame: 1 week, 3 weeks and 8 weeks
To assess potential skin abnormalities resulting from kinesio taping, a questionnaire will be distributed among the participants. This questionnaire is designed based on the decubitus stages. Additionally, in case of skin abnormalities or rashes, participants will be requested to upload a photograph of the affected area for independent evaluation of the skin condition.
1 week, 3 weeks and 8 weeks
evaluating use of oral analgesics by questionnaire
Time Frame: after 1 week, 3 weeks and 8 weeks
To evaluate the utilization of oral analgesics, a questionnaire is administered to the participants to ascertain the type of medication employed, as well as to quantify the frequency and dosage of its usage.
after 1 week, 3 weeks and 8 weeks
evaluating independence, pattern of activity and course of pain complaints by Groningen Activity Restriction Scale (GARS)
Time Frame: after 1 week, 3 weeks and 8 weeks
To delineate the independence, pattern of activity, and course of pain complaints, we employ the Groningen Activity Restriction Scale (GARS).
after 1 week, 3 weeks and 8 weeks
Evaluating comfort and patient satisfaction by Global Perceived Effect (GPE-DV)
Time Frame: after 15 minutes, 1 week, 3 weeks and 8 weeks
To gauge comfort and patient satisfaction, the Global Perceived Effect (GPE-DV) is utilized as a measurement tool.
after 15 minutes, 1 week, 3 weeks and 8 weeks
Evaluating the need of physiotherapy by questionnaire
Time Frame: 8 weeks
To gain insight into whether patients avail or have availed themselves of physiotherapy, a questionnaire is dispatched after 8 weeks, encompassing queries regarding the utilization of physiotherapy during the treatment period, its frequency, and the nature of the treatment sought.
8 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
clinical meaningful pain reduction for the different intervention arms
Time Frame: 15 min, 1 week, 3 weeks and 8 weels
In an exploratory analysis, we would like to assess in a subgroup analysis if the number of patients with clinically meaningful pain reduction after 15 minutes, 1 week, 3 weeks and 8 weeks for the different intervention arms differs between patients with uncomplicated rib fracture, disruption of the AC-joint, clavicle fracture, and proximal humeral fracture (using the BPI-NRS)
15 min, 1 week, 3 weeks and 8 weels

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Mireille Bakker, MSc, OLVG
  • Study Chair: Maro Sandel, MD, PhD, OLVG
  • Study Chair: Carel Goslings, MD, PhD, OLVG
  • Study Chair: Janneke Schuitenmaker, MSc, OLVG

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2023

Primary Completion (Estimated)

March 31, 2025

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

July 17, 2023

First Submitted That Met QC Criteria

July 27, 2023

First Posted (Actual)

August 4, 2023

Study Record Updates

Last Update Posted (Actual)

August 4, 2023

Last Update Submitted That Met QC Criteria

July 27, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Acromioclavicular Joint Dislocation

Clinical Trials on sham tape (leukotape classic)

3
Subscribe